Dermatology News

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

ORLANDO — A speaker at the American Society for Dermatologic Surgery Annual Meeting highlighted the importance of dermatologists using correct pronouns when talking to their transgender or nonbinary patients.

Healio spoke with Darin Messina, PhD, on the significance and practical impact of the FDA’s most recent approval of Botox Cosmetic for platysma bands.

ORLANDO — A survey found Black women were less likely to seek treatment for certain highly bothersome aesthetic concerns, according to a speaker at the American Society for Dermatologic Surgery Annual Meeting.

Suicide rates for individuals diagnosed with cancer increased over the past 2 decades, according to results of a retrospective study.

ORLANDO — Repeated injections of relabotulinumtoxinA over the span of a year were safe for the treatment of glabellar and lateral canthal lines, according to a presentation at the American Society for Dermatologic Surgery Annual Meeting.

BOSTON — Patients with moderate to severe atopic dermatitis experienced relief with lebrikizumab for 52 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ORLANDO — A speaker at the American Society for Dermatologic Surgery Annual Meeting discussed the treatment options for positive margins after standard excision of cutaneous melanoma.

The FDA has approved Emrosi for the treatment of rosacea in adults, Journey Medical Corporation announced in a press release.